Branch Retinal Vein Occlusion With Macular Edema
8
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
63%
5 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
Ocular Safety and Usability Study for FYB201 PFS
Ocular Safety and Usability Study for FYB203 PFS
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO
Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion
Intravitreal Injections of Ziv-aflibercept for Macular Diseases